CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $12.56B, above the global median of $1.2B
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.56BUSDvs all stocks (USD)
Trailing P/E
78.16xvs Medical Devices peers
Revenue (TTM)
1.50BUSDvs all stocks (USD)
Profit Margin
10.67%vs Medical Devices peers
Beta
0.6980xvs all stocks
52-Week Change
26.72%vs all stocks
Market Capitalization
12.56BUSDvs all stocks (USD)
Enterprise Value
12.11BUSDvs all stocks (USD)
Trailing P/E
78.16xvs Medical Devices peers
Forward P/E
52.00xvs Medical Devices peers
PEG Ratio
-3.33xvs Medical Devices peers
Price to Sales (TTM)
8.35xvs Medical Devices peers
Price to Book (MRQ)
8.21xvs Medical Devices peers
Enterprise to Revenue
8.05xvs Medical Devices peers
Enterprise to EBITDA
59.30xvs Medical Devices peers
Gross Margin
67.93%vs Medical Devices peers
Profit Margin
10.67%vs Medical Devices peers
Operating Margin
10.52%vs Medical Devices peers
Return on Assets (TTM)
6.42%vs Medical Devices peers
Return on Equity (TTM)
11.37%vs Medical Devices peers
Revenue (TTM)
1.50BUSDvs all stocks (USD)
Revenue per Share (TTM)
38.36USDUpdated Sep 28, 2026Quarterly Revenue Growth
14.90%vs Medical Devices peers
Gross Profit (TTM)
1.02BUSDvs all stocks (USD)
EBITDA (TTM)
222.27MUSDvs all stocks (USD)
Net Income (TTM)
160.59MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-23.10%vs Medical Devices peers
Operating Cash Flow (TTM)
277.80MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
161.10MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
1.40BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
461.23MUSDFY2025 · Dec 31, 2025Gross Profit
942.44MUSDFY2025 · Dec 31, 2025Operating Income
189.25MUSDvs all stocks (USD)
Pre-tax Income
205.13MUSDFY2025 · Dec 31, 2025Income Tax Expense
27.44MUSDFY2025 · Dec 31, 2025Net Income
177.69MUSDFY2025 · Dec 31, 2025EBIT
206.44MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
223.91MUSDFY2025 · Dec 31, 2025Research & Development
89.77MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
663.42MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.29MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.31MUSDFY2025 · Dec 31, 2025EPS (Basic)
4.57USDFY2025 · Dec 31, 2025EPS (Diluted)
4.52USDFY2025 · Dec 31, 2025Basic Shares Outstanding
38.92MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
38.92MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
177.69MUSDFY2025 · Dec 31, 2025Operating Cash Flow
232.68MUSDFY2025 · Dec 31, 2025Free Cash Flow
168.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
186.90MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
177.69MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
17.47MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
21.03MUSDFY2025 · Dec 31, 2025Stock-based Compensation
59.21MUSDFY2025 · Dec 31, 2025Other Non-cash Items
205.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-19.51MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.07MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-26.48MUSDFY2025 · Dec 31, 2025Capital Expenditures
-63.73MUSDFY2025 · Dec 31, 2025Purchase of Investments
-355.74MUSDFY2025 · Dec 31, 2025Sale of Investments
14.88MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-404.59MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-2.48MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-2.80MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.29MUSDFY2025 · Dec 31, 2025Shares Outstanding
39.39MSharesUpdated Sep 28, 2026Float Shares
38.27MSharesUpdated Sep 28, 2026Shares Short
1.81MSharesUpdated Sep 28, 2026Short Ratio
6.68daysvs all stocks
Short % of Shares Outstanding
5.27%vs all stocks
% Held by Insiders
2.90%vs all stocks
% Held by Institutions
88.36%vs all stocks
Total Cash (MRQ)
658.80MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
16.73USDUpdated Sep 28, 2026Total Debt (MRQ)
212.71MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1390xvs Medical Devices peers
Current Ratio (MRQ)
5.75xvs Medical Devices peers
Book Value per Share (MRQ)
38.86USDUpdated Sep 28, 2026Total Assets
1.83BUSDvs all stocks (USD)
Total Current Assets
1.22BUSDFY2025 · Dec 31, 2025Total Liabilities
398.92MUSDFY2025 · Dec 31, 2025Total Non-current Assets
609.84MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
215.78MUSDFY2025 · Dec 31, 2025Total Current Liabilities
183.13MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
186.90MUSDFY2025 · Dec 31, 2025Other Short-term Investments
357.92MUSDFY2025 · Dec 31, 2025Accounts Receivable
190.02MUSDFY2025 · Dec 31, 2025Inventory
431.55MUSDFY2025 · Dec 31, 2025Accounts Payable
34.74MUSDFY2025 · Dec 31, 2025Short-term Debt
16.23MUSDFY2025 · Dec 31, 2025Long-term Debt
203.47MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
12.32MUSDFY2025 · Dec 31, 2025Common Stock (Book)
39.00KUSDFY2025 · Dec 31, 2025Retained Earnings
237.69MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.43BUSDvs all stocks (USD)
52-Week Low
221.26USDUpdated Sep 28, 202652-Week High
362.41USDUpdated Sep 28, 202652-Week Change
26.72%vs all stocks
Beta
0.6980xvs all stocks
50-Day MA
321.56USDUpdated Sep 28, 2026200-Day MA
326.37USDUpdated Sep 28, 2026Avg 10-Day Volume
521.05KSharesUpdated Sep 28, 2026Avg 30-Day Volume
345.74KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
4.08USDUpdated Sep 28, 2026Other Income / Expense
893.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $12.56B, above the global median of $1.2BNotable
Market cap (USD): 12,560,893,175Global Median: 1,201,862,193
Revenue is $1.5B, above the global median of $558.46MNotable
Revenue (USD): 1,504,873,984Global Median: 558,459,881.051
Levered free cash flow is $161.1M, above the global median of $18.92MNotable
Levered free cash flow (USD): 161,100,128Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Corcept Therapeutics Incorporated
Tier 1ProductionApproval-Gated PipelineRule
Shanghai United Imaging Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Summit Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
ALTEOGEN Inc.
Tier 1ProductionApproval-Gated PipelineRule
BridgeBio Pharma, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Halozyme Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Swedish Orphan Biovitrum AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang NHU Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Madrigal Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cipla Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Finolex Industries Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Flytech Technology Co., Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Federal-Mogul Goetze (India) Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities